secukinumab 300 mg Q4W + secukinumab 300 mg Q2W
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris
Conditions
Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris
Trial Timeline
Jul 27, 2020 → May 3, 2022
NCT ID
NCT04300296About secukinumab 300 mg Q4W + secukinumab 300 mg Q2W
secukinumab 300 mg Q4W + secukinumab 300 mg Q2W is a phase 2 stage product being developed by Novartis for Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris. The current trial status is completed. This product is registered under clinical trial identifier NCT04300296. Target conditions include Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04300296 | Phase 2 | Completed |
Competing Products
12 competing products in Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LP-10 (Liposomal Tacrolimus) | Lipella Pharmaceuticals | Phase 2 | 44 |
| Tacrolimus cream + Clobetasol cream | Astellas Pharma | Phase 2 | 52 |
| Baricitinib 4 milligram Oral Tablet | Eli Lilly | Phase 2 | 52 |
| pimecrolimus and clobetasol + clobetasol 0.05% cream | Novartis | Phase 2 | 52 |
| Pimecrolimus 1% cream | Novartis | Phase 2 | 52 |
| Apremilast + Placebo | Amgen | Phase 2 | 51 |
| Deucravacitinib | Bristol Myers Squibb | Phase 2 | 51 |
| Dupilumab + Placebo | Sanofi | Phase 3 | 76 |
| Dupilumab + Placebo | Sanofi | Phase 3 | 76 |
| Amevive (Alefacept) + Placebo | Biogen | Phase 2 | 49 |
| Ruxolitinib cream + Vehicle cream | Incyte | Phase 2 | 49 |
| Ruxolitinib cream + Vehicle cream | Incyte | Phase 2 | 49 |